The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, presents real-world findings from the prospective PREAMBLE study (NCT01838512) assessing rates and reasons for treatment discontinuation in patients with multiple myeloma (MM). The data indicated that discontinuation rates are high in the real-world setting, driven primarily by treatment fatigue and adverse events. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
PREAMBLE is one of the largest prospective studies running over 10 years across Europe and in the US, recruiting both newly diagnosed myeloma patients as well as relapsed myeloma patients. We now have increasingly newer treatment options for patients with myeloma. Therefore, patients would like to come off treatment and have treatment-free intervals. What we analyzed in our data set in the PREAMBLE is to start to look at why patients were discontinuing therapy...
PREAMBLE is one of the largest prospective studies running over 10 years across Europe and in the US, recruiting both newly diagnosed myeloma patients as well as relapsed myeloma patients. We now have increasingly newer treatment options for patients with myeloma. Therefore, patients would like to come off treatment and have treatment-free intervals. What we analyzed in our data set in the PREAMBLE is to start to look at why patients were discontinuing therapy. And this is an important piece of observation which will help us design future clinical studies. Clearly, there are high levels of discontinuation that we see in real-world practice in comparison to clinical trials. And there are multiple reasons that we are noticing within this kind of PREAMBLE data set, but certainly, fatigue with treatment, continuous treatment, appears to be one of the important reasons along with adverse events noted. So this is some early data that we’re starting to put out around discontinuation and this helps us to start to frame our thinking around what patients really want when we give them effective therapies in the newly diagnosed setting as well as in the relapse setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
